CHM is only a first mover in CDH17 in the CAR-T space but overall, they're coming second to Boehringer Ingelheim's TRAILR2/CDH17 bi-specific monoclonal antibody who is already running phase 1 trials (https://clinicaltrials.gov/ct2/show/NCT04137289). They're running the trial on 140 patients and have been running it since 2019. I would watch their results and see how they validate CDH17 as a target receptor.
https://pro.boehringer-ingelheim.com/inoncology/ourpipeline/trailr2cdh17-antibody
CHM is only a first mover in CDH17 in the CAR-T space but...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |